Middle East respiratory syndrome

Seegene to pave way for PCR testing at local clinics with EU-approved multiplex test and fully automated PCR solution

Retrieved on: 
Wednesday, June 29, 2022

This is expected to help small hospitals, local clinics, and public health centers effectively identify COVID-19, influenza A and B and respiratory syncytial virus (RSV).

Key Points: 
  • This is expected to help small hospitals, local clinics, and public health centers effectively identify COVID-19, influenza A and B and respiratory syncytial virus (RSV).
  • The targets include three distinct COVID-19 genes (S, RdRp, N) to reliably identify positive cases even as new variants emerge.
  • As AIOS is a fully automated (sample in result out) system, it can be operated by those without PCR experience.
  • *Syndromic testing refers to the process of simultaneously targeting multiple pathogens that have similar symptoms using a single test.

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Retrieved on: 
Wednesday, May 25, 2022

SEOUL, South Korea, May 25, 2022 /PRNewswire/ -- Seegene Inc. (KQ096530), South Korea's leading molecular diagnostics (MDx) company, today unveiled a global initiative for preemptive and routine PCR testing to help individuals stay safe and healthy while living in the COVID-19 era. Dr. Jong-Yoon Chun, CEO of Seegene, says the initiative is designed to help people safely return to normalcy and contribute to global efforts to terminate COVID-19 and prevent future outbreaks.

Key Points: 
  • Dr. Jong-Yoon Chun, CEO of Seegene, says the initiative is designed to help people safely return to normalcy and contribute to global efforts to terminate COVID-19 and prevent future outbreaks.
  • Seegene's initiative dubbed 'In-life PCR,' entails 1) asymptomatic testing for early virus detection 2) syndromic respiratory testing as anti-virus restrictions are eased and 3) boosting PCR test accessibility through affordable pricing.
  • "The '$12 PCR testing' campaign is expected to help Seegene deliver its commitment to making molecular diagnostics accessible to anyone," said Dr. Chun.
  • "I'm certain that routine PCR testing will be the best solution to help end the COVID-19 pandemic.

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Retrieved on: 
Wednesday, May 25, 2022

SEOUL, South Korea, May 25, 2022 /PRNewswire/ -- Seegene Inc. (KQ096530), South Korea's leading molecular diagnostics (MDx) company, today unveiled a global initiative for preemptive and routine PCR testing to help individuals stay safe and healthy while living in the COVID-19 era. Dr. Jong-Yoon Chun, CEO of Seegene, says the initiative is designed to help people safely return to normalcy and contribute to global efforts to terminate COVID-19 and prevent future outbreaks.

Key Points: 
  • Dr. Jong-Yoon Chun, CEO of Seegene, says the initiative is designed to help people safely return to normalcy and contribute to global efforts to terminate COVID-19 and prevent future outbreaks.
  • Seegene's initiative dubbed 'In-life PCR,' entails 1) asymptomatic testing for early virus detection 2) syndromic respiratory testing as anti-virus restrictions are eased and 3) boosting PCR test accessibility through affordable pricing.
  • "The '$12 PCR testing' campaign is expected to help Seegene deliver its commitment to making molecular diagnostics accessible to anyone," said Dr. Chun.
  • "I'm certain that routine PCR testing will be the best solution to help end the COVID-19 pandemic.

Seegene unveils world's first commercialized '3 Ct' PCR assay

Retrieved on: 
Tuesday, April 26, 2022

In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target).

Key Points: 
  • In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target).
  • Due to technological limitations, the conventional real-time PCR technique finds the Ct value of one target in one channel.
  • But Seegene's '3 Ct' technology can provide the Ct value of three targets in one channel without compromising sensitivity and specificity.
  • Using five channels in a single tube, Seegene can provide quantitative data for a total of 15 targets.

Seegene unveils world's first commercialized '3 Ct' PCR assay

Retrieved on: 
Tuesday, April 26, 2022

In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target).

Key Points: 
  • In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target).
  • Due to technological limitations, the conventional real-time PCR technique finds the Ct value of one target in one channel.
  • Using five channels in a single tube, Seegene can provide quantitative data for a total of 15 targets.
  • "Seegene is a company very involved in the development of molecular diagnostics tests for the detection of different pathogens.

Seegene's Allplex™ RV Master Assay receives Australian TGA approval, European CE-IVD mark

Retrieved on: 
Wednesday, April 6, 2022

Seegene's AllplexRV Master Assay can distinguish 21 targets for 19 different respiratory viruses, including COVID-19, flu, and common colds.

Key Points: 
  • Seegene's AllplexRV Master Assay can distinguish 21 targets for 19 different respiratory viruses, including COVID-19, flu, and common colds.
  • The AllplexRV Master Assaywas developed based on Seegene's decades-long know-how and applies patent technologies, like DPO, TOCEand MuDT(see table 2).
  • The AllplexRV Master Assay has been designed in consideration of such circumstances as countries shift policies to get everyday life back to normal.
  • "The assay is expected to be well-utilized as winter approaches in Australia and South America and as the world turns to live with COVID-19 endemically."

Baebies Earns CE Mark for FINDER SARS-CoV-2 Point-of-Care Testing Platform

Retrieved on: 
Friday, April 1, 2022

DURHAM, NC / ACCESSWIRE / March 24, 2022 / Baebies (R) announced today it has received CE Mark for its FINDER(R) SARS-CoV-2 point-of-care test, which performs RT-PCR testing to detect SARS-CoV-2 on the FINDER 1.5 Instrument.

Key Points: 
  • DURHAM, NC / ACCESSWIRE / March 24, 2022 / Baebies (R) announced today it has received CE Mark for its FINDER(R) SARS-CoV-2 point-of-care test, which performs RT-PCR testing to detect SARS-CoV-2 on the FINDER 1.5 Instrument.
  • The CE Mark confirms that the FINDER SARS-CoV-2 test meets the requirements of the European Medical Devices Directive, which now allows Baebies to commercialize the test across the European Union and other CE Mark geographies.
  • The FINDER SARS-CoV-2 testing platform leverages Baebies' core digital microfluidics (DMF) technology to streamline and miniaturize the conventional RT-PCR process, enabling lab-quality results directly at the point of care.
  • "CE Mark is an important regulatory milestone for Baebies to expand the reach of our FINDER SARS-CoV-2 test and introduce the power of digital microfluidics to new markets across the world," said Richard West, CoFounder and Chief Executive Officer of Baebies.

QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2

Retrieved on: 
Tuesday, November 2, 2021

It leverages the easy-to-use QIAstat-Dx modular cartridge-based system to deliver fast results that require no additional sample preparation.

Key Points: 
  • It leverages the easy-to-use QIAstat-Dx modular cartridge-based system to deliver fast results that require no additional sample preparation.
  • The viruses produce similar respiratory symptoms, making it challenging to clinicians to diagnose exactly which one a patient is suffering from to make the right treatment decisions.
  • By adding this new test to our growing QIAstat-Dx testing menu, we are taking another step to increase the platforms value for customers beyond the pandemic.
  • With QIAGEN chemistries for sample processing and analysis built in, the QIAstat-Dx instrument delivers results in about one hour.

Seegene Unveils Fully Automated Molecular Testing System at the 2021 AACC

Retrieved on: 
Monday, September 27, 2021

Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in the Atlanta, GA, United States

Key Points: 
  • Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in the Atlanta, GA, United States
    AIOS is the MDx system that integrates Seegene's liquid handler and real-time PCR instruments.
  • SEOUL,South Korea, Sept. 27, 2021 /PRNewswire/ --Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics, is unveiling a fully automated PCRtesting (MDx) system at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo to be held on September 26-30, 2021, in Atlanta, GA, USA.
  • During this event, Seegene will be unveiling AIOS - its first fully automated MDx system.
  • AIOSisfully automated syndromic MDx system designed in a modular concept while it compiles Seegene's cutting-edge high multiplex real-time PCR technologies.

Seegene Unveils Fully Automated Molecular Testing System at the 2021 AACC

Retrieved on: 
Monday, September 27, 2021

Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in the Atlanta, GA, United States

Key Points: 
  • Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in the Atlanta, GA, United States
    AIOS is the MDx system that integrates Seegene's liquid handler and real-time PCR instruments.
  • SEOUL,South Korea, Sept. 27, 2021 /PRNewswire/ --Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics, is unveiling a fully automated PCRtesting (MDx) system at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo to be held on September 26-30, 2021, in Atlanta, GA, USA.
  • During this event, Seegene will be unveiling AIOS - its first fully automated MDx system.
  • AIOSisfully automated syndromic MDx system designed in a modular concept while it compiles Seegene's cutting-edge high multiplex real-time PCR technologies.